COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05074043|
Recruitment Status : Completed
First Posted : October 12, 2021
Last Update Posted : October 12, 2021
We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.
All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.
|Condition or disease||Intervention/treatment|
|Mucormycosis||Combination Product: antiviral, surgical|
|Study Type :||Observational|
|Actual Enrollment :||433 participants|
|Official Title:||COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital|
|Actual Study Start Date :||March 1, 2021|
|Actual Primary Completion Date :||June 30, 2021|
|Actual Study Completion Date :||July 30, 2021|
covid 19 proven by clinical, PCR. not associated with mucor
covid19 associated with mucor
covid19 associated with mucor proven by clinical, histopathological
Combination Product: antiviral, surgical
- incidence of covid19 associated mucor [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05074043
|Asyut, Egypt, 11711|